Display options
Cite
Zhang Y, Chen K, Dai W, et al. Combination therapy of bezafibrate and ursodeoxycholic acid for primary biliary cirrhosis: A meta-analysis. Hepatol Res. 2014;45(1):48-58doi: 10.1111/hepr.12373.
Zhang, Y., Chen, K., Dai, W., Xia, Y., Wang, F., Shen, M., Cheng, P., Wang, C., Yang, J., Zhu, R., Zhang, H., Li, J., Zheng, Y., Wang, J., Lu, J., Zhou, Y., & Guo, C. (2015). Combination therapy of bezafibrate and ursodeoxycholic acid for primary biliary cirrhosis: A meta-analysis. Hepatology research : the official journal of the Japan Society of Hepatology, 45(1), 48-58. https://doi.org/10.1111/hepr.12373
Zhang, Yan, et al. "Combination therapy of bezafibrate and ursodeoxycholic acid for primary biliary cirrhosis: A meta-analysis." Hepatology research : the official journal of the Japan Society of Hepatology vol. 45,1 (2015): 48-58. doi: https://doi.org/10.1111/hepr.12373
Zhang Y, Chen K, Dai W, Xia Y, Wang F, Shen M, Cheng P, Wang C, Yang J, Zhu R, Zhang H, Li J, Zheng Y, Wang J, Lu J, Zhou Y, Guo C. Combination therapy of bezafibrate and ursodeoxycholic acid for primary biliary cirrhosis: A meta-analysis. Hepatol Res. 2015 Jan;45(1):48-58. doi: 10.1111/hepr.12373. Epub 2014 Jul 28. PMID: 24934524.
Copy Download .nbib Format: NLM
Share it on

Hepatol Res. 2015 Jan;45(1):48-58. doi: 10.1111/hepr.12373. Epub 2014 Jul 28.

Combination therapy of bezafibrate and ursodeoxycholic acid for primary biliary cirrhosis: A meta-analysis.

Hepatology research : the official journal of the Japan Society of Hepatology

Yan Zhang, Kan Chen, Weiqi Dai, Yujing Xia, Fan Wang, Miao Shen, Ping Cheng, Chengfen Wang, Jing Yang, Rong Zhu, Huawei Zhang, Jingjing Li, Yuanyuan Zheng, Junshan Wang, Jie Lu, Yingqun Zhou, Chuanyong Guo

Affiliations

  1. Department of Gastroenterology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, China.

PMID: 24934524 DOI: 10.1111/hepr.12373

Abstract

The aim of this study was to assess the efficiency and safety of combination therapy of ursodeoxycholic acid (UDCA) and bezafibrate for primary biliary cirrhosis. A meta-analysis of all long-term randomized controlled trials comparing the combination of UDCA and bezafibrate with UDCA monotherapy was performed via electronic searches. Seven trials, which included 177 patients, were assessed. Combination therapy with UDCA and bezafibrate was more effective than UDCA monotherapy in improving liver biochemistry, alkaline phosphatase (mean difference [MD], -146.15 IU/L; 95% confidence interval [CI], -193.58 to -98.72; P < 0.00001), γ-glutamyltransferase (MD, -20.64 IU/L; 95% CI, -30.86 to -10.43; P < 0.0001), immunoglobulin M (MD, -90.96 mg/dL; 95% CI, -137.36 to -44.56; P = 0.0001) and triglycerides (MD, -15.49 mg/dL; 95% CI, -30.25 to -0.74; P = 0.04). However, their effects on pruritus (odds ratio [OR], 0.82; 95% CI, 0.30-2.24; P = 0.70) and alanine aminotransferase (MD, -8.41 IU/L; 95% CI, -22.57 to 5.75; P = 0.24) did not differ significantly. This meta-analysis revealed no significant differences in the incidence of all-cause mortality (OR, 0.72; 95% CI, 0.10-5.49; P = 0.75) and adverse events (OR, 0.35; 95% CI, 0.07-1.84; P = 0.22) between patients treated with combination therapy and those treated with monotherapy. In this meta-analysis, combination therapy with UDCA and bezafibrate was more effective than UDCA monotherapy. Combination therapy improved liver biochemistry, but did not improve clinical symptoms, incidence of death or adverse events more effectively than monotherapy.

© 2014 The Japan Society of Hepatology.

Keywords: bezafibrate; meta-analysis; primary biliary cirrhosis; ursodeoxycholic acid

Publication Types